A Phase 2 interventional study of Multivalent group B streptococcus vaccine and Placebo in Group B Streptococcal Infections, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-02.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Streptococcal Infections with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Streptococcal Infections · United States.
Among the 24 studies in Streptococcal Infections with a site in United States, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 2, and was the 16th registered.
147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
Browse Streptococcal Infections studies →1 of the 24 studies in Streptococcal Infections with a site in United States is open now. Recruiting first, the newest first:
SalivIQ Diagnostics, Inc. · Sites in United States
Ages 3+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 1 · Phase 4 1
First in 1993; this study’s year is marked. 1 started in 2017.
This study's enrollment of 365 is above the median of 270 across 106 interventional studies indexed under Streptococcal Infections.
Median enrollment 365 across the 17 interventional studies, 426 across the 7 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 24 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Streptococcal Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Streptococcal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07891728SalivIQ Diagnostics, Inc.A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Streptococcal Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Multivalent group B streptococcus vaccine
Biological: Multivalent group B streptococcus vaccine
Saline control
Biological: Placebo
Various formulations at three dose levels
Saline Control
Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade
Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\<8.0 g/dL; leukocyte increase:G1: 10.8-15\*10\^9/Liter\[L\],G2:\>15-20\*10\^9/L, G3:\>20-25\*10\^9/L, G4:\>25\*10\^9/L,leukocyte decrease: G1: 2.5-3.5\*10\^9/L, G2: 1.5-\<2.5\*10\^9/L, G3: 1-\<1.5\*10\^9/L, G4:\<1\*10\^9/L; neutrophil decrease:G1: 1.5-2\*10\^9/L, G2:1-\<1.5\*10\^9/L, G3:0.5-\<1\*10\^9/L,G4:\<0.5\*10\^9/L; platelets:G1: 125-140\*10\^9/L, G2:100-124\*10\^9/L, G3:25-99\*10\^9/L, G4:\<25\*10\^9/L; eosinophils: G1: 0.65-1.5\*10\^9/L, G2:\>1.5-5\*10\^9/L, G3:\>5\*10\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \*ULN, G2:2.6-5.0\*ULN, G3:5.1-10\*ULN, G4:\>10\*ULN; alkaline phosphatase:G1: 1.1-2\*ULN, G2:2.1-3\*ULN, G3:3.1-10\*ULN, G4:\>10\*ULN; Bilirubin:G1: 1.1-1.5\*ULN, G2: 1.26-2\*ULN,G3: 1.51-3.0\*ULN,G4:\>1.75\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\>=1 participant with abnormality are reported only.
Time frame: 1 week after vaccination
Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination
Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \[cm\]), moderate (greater than \[\>\] 5.0-10.0 cm) and severe (\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.
Time frame: Within 14 days after vaccination
Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination
Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\[hr\]),moderate(some interference with activity/\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.
Time frame: Within 14 days after vaccination
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.
Time frame: Within 1 month after vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
Time frame: Within 6 months after vaccination
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.
Time frame: Within 6 months after vaccination
GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination
Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.
Time frame: 1 month after vaccination
| Milestone | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 53 | 52 | 52 | 52 | 52 | 52 | 52 |
| Vaccinated | 52 | 52 | 52 | 52 | 52 | 52 | 52 |
| Completed | 50 | 50 | 46 | 50 | 51 | 50 | 51 |
| Not completed | 3 | 2 | 6 | 2 | 1 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 5 | 2 | 1 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\<8.0 g/dL; leukocyte increase:G1: 10.8-15\*10\^9/Liter\[L\],G2:\>15-20\*10\^9/L, G3:\>20-25\*10\^9/L, G4:\>25\*10\^9/L,leukocyte decrease: G1: 2.5-3.5\*10\^9/L, G2: 1.5-\<2.5\*10\^9/L, G3: 1-\<1.5\*10\^9/L, G4:\<1\*10\^9/L; neutrophil decrease:G1: 1.5-2\*10\^9/L, G2:1-\<1.5\*10\^9/L, G3:0.5-\<1\*10\^9/L,G4:\<0.5\*10\^9/L; platelets:G1: 125-140\*10\^9/L, G2:100-124\*10\^9/L, G3:25-99\*10\^9/L, G4:\<25\*10\^9/L; eosinophils: G1: 0.65-1.5\*10\^9/L, G2:\>1.5-5\*10\^9/L, G3:\>5\*10\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \*ULN, G2:2.6-5.0\*ULN, G3:5.1-10\*ULN, G4:\>10\*ULN; alkaline phosphatase:G1: 1.1-2\*ULN, G2:2.1-3\*ULN, G3:3.1-10\*ULN, G4:\>10\*ULN; Bilirubin:G1: 1.1-1.5\*ULN, G2: 1.26-2\*ULN,G3: 1.51-3.0\*ULN,G4:\>1.75\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\>=1 participant with abnormality are reported only.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Hemoglobin: Grade 1 | 0 | 6.3 | 12.5 | 0 | 0 | 6.3 | 0 |
| Hemoglobin: Grade 2 | 6.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets: Grade 1 | 0 | 0 | 6.3 | 6.7 | 0 | 0 | 0 |
| Leukocyte decrease:Grade 1 | 6.3 | 6.3 | 0 | 0 | 0 | 0 | 0 |
| Leukocyte increase: Grade 1 | 0 | 0 | 0 | 0 | 0 | 6.3 | 0 |
| Leukocyte increase: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4.2 |
| Neutrophils decrease(Absolute): Grade 1 | 6.3 | 18.8 | 0 | 0 | 0 | 6.3 | 0 |
| Neutrophils decrease (Absolute): Grade 2 | 0 | 0 | 0 | 0 | 6.3 | 0 | 0 |
| Blood urea nitrogen: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4.2 |
| Blood urea nitrogen: Grade 2 | 0 | 0 | 0 | 0 | 0 | 6.3 | 0 |
| Aspartate aminotransferase: Grade 1 | 0 | 0 | 0 | 0 | 6.3 | 0 | 0 |
| Aspartate aminotransferase: Grade 3 | 0 | 6.3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase: Grade 1 | 0 | 6.3 | 0 | 0 | 12.5 | 0 | 0 |
| Bilirubin in presence of normal AST and ALT:Grade1 | 0 | 0 | 6.3 | 0 | 0 | 0 | 0 |
| Alkaline phosphate: Grade 1 | 0 | 0 | 6.3 | 0 | 0 | 0 | 0 |
Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \[cm\]), moderate (greater than \[\>\] 5.0-10.0 cm) and severe (\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Pain:Any | 53.8 (39.5 to 67.8) | 32.7 (20.3 to 47.1) | 48.1 (34.0 to 62.4) | 38.5 (25.3 to 53.0) | 51.9 (37.6 to 66.0) | 25.0 (14.0 to 38.9) | 15.4 (6.9 to 28.1) |
| Pain:Mild | 51.9 (37.6 to 66.0) | 28.8 (17.1 to 43.1) | 44.2 (30.5 to 58.7) | 36.5 (23.6 to 51.0) | 42.3 (28.7 to 56.8) | 19.2 (9.6 to 32.5) | 13.5 (5.6 to 25.8) |
| Pain:Moderate | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 9.6 (3.2 to 21.0) | 5.8 (1.2 to 15.9) | 1.9 (0.0 to 10.3) |
| Pain:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Pain:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Redness:Any | 0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Redness:Mild | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Redness:Moderate | 0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Redness:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Redness:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Swelling:Any | 0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) | 5.8 (1.2 to 15.9) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Swelling:Mild | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) | 5.8 (1.2 to 15.9) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Swelling:Moderate | 0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Swelling:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Swelling:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\[hr\]),moderate(some interference with activity/\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Fever:>=38.0 degree C | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) |
| Fever:38.0 to 38.4 degree C | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) |
| Fever:38.5 to 38.9 degree C | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) |
| Fever:39.0 to 40.0 degree C | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Fever:>40.0 degree C | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Nausea/vomiting: Any | 13.5 (5.6 to 25.8) | 5.8 (1.2 to 15.9) | 11.5 (4.4 to 23.4) | 17.3 (8.2 to 30.3) | 9.6 (3.2 to 21.0) | 11.5 (4.4 to 23.4) | 21.2 (11.1 to 34.7) |
| Nausea/vomiting: Mild | 9.6 (3.2 to 21.0) | 3.8 (0.5 to 13.2) | 9.6 (3.2 to 21.0) | 11.5 (4.4 to 23.4) | 7.7 (2.1 to 18.5) | 9.6 (3.2 to 21.0) | 13.5 (5.6 to 25.8) |
| Nausea/vomiting: Moderate | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 5.8 (1.2 to 15.9) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 7.7 (2.1 to 18.5) |
| Nausea/vomiting: Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Nausea/vomiting: Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Diarrhea:Any | 13.5 (5.6 to 25.8) | 21.2 (11.1 to 34.7) | 13.5 (5.6 to 25.8) | 21.2 (11.1 to 34.7) | 21.2 (11.1 to 34.7) | 17.3 (8.2 to 30.3) | 11.5 (4.4 to 23.4) |
| Diarrhea:Mild | 11.5 (4.4 to 23.4) | 21.2 (11.1 to 34.7) | 11.5 (4.4 to 23.4) | 13.5 (5.6 to 25.8) | 19.2 (9.6 to 32.5) | 11.5 (4.4 to 23.4) | 5.8 (1.2 to 15.9) |
| Diarrhea:Moderate | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) | 0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) | 5.8 (1.2 to 15.9) |
| Diarrhea:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Diarrhea:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Headache:Any | 40.4 (27.0 to 54.9) | 36.5 (23.6 to 51.0) | 32.7 (20.3 to 47.1) | 38.5 (25.3 to 53.0) | 40.4 (27.0 to 54.9) | 30.8 (18.7 to 45.1) | 42.3 (28.7 to 56.8) |
| Headache:Mild | 26.9 (15.6 to 41.0) | 21.2 (11.1 to 34.7) | 15.4 (6.9 to 28.1) | 11.5 (4.4 to 23.4) | 28.8 (17.1 to 43.1) | 11.5 (4.4 to 23.4) | 23.1 (12.5 to 36.8) |
| Headache:Moderate | 13.5 (5.6 to 25.8) | 13.5 (5.6 to 25.8) | 15.4 (6.9 to 28.1) | 25.0 (14.0 to 38.9) | 11.5 (4.4 to 23.4) | 17.3 (8.2 to 30.3) | 15.4 (6.9 to 28.1) |
| Headache:Severe | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) |
| Headache:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Fatigue/tiredness: Any | 42.3 (28.7 to 56.8) | 32.7 (20.3 to 47.1) | 34.6 (22.0 to 49.1) | 26.9 (15.6 to 41.0) | 50.0 (35.8 to 64.2) | 38.5 (25.3 to 53.0) | 34.6 (22.0 to 49.1) |
| Fatigue/tiredness: Mild | 19.2 (9.6 to 32.5) | 11.5 (4.4 to 23.4) | 9.6 (3.2 to 21.0) | 7.7 (2.1 to 18.5) | 25.0 (14.0 to 38.9) | 19.2 (9.6 to 32.5) | 9.6 (3.2 to 21.0) |
| Fatigue/tiredness: Moderate | 23.1 (12.5 to 36.8) | 21.2 (11.1 to 34.7) | 21.2 (11.1 to 34.7) | 15.4 (6.9 to 28.1) | 25.0 (14.0 to 38.9) | 19.2 (9.6 to 32.5) | 19.2 (9.6 to 32.5) |
| Fatigue/tiredness: Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 3.8 (0.5 to 13.2) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) |
| Fatigue/tiredness:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Muscle pain:Any | 17.3 (8.2 to 30.3) | 25.0 (14.0 to 38.9) | 19.2 (9.6 to 32.5) | 19.2 (9.6 to 32.5) | 19.2 (9.6 to 32.5) | 23.1 (12.5 to 36.8) | 19.2 (9.6 to 32.5) |
| Muscle pain:Mild | 9.6 (3.2 to 21.0) | 17.3 (8.2 to 30.3) | 7.7 (2.1 to 18.5) | 11.5 (4.4 to 23.4) | 13.5 (5.6 to 25.8) | 17.3 (8.2 to 30.3) | 5.8 (1.2 to 15.9) |
| Muscle pain:Moderate | 7.7 (2.1 to 18.5) | 7.7 (2.1 to 18.5) | 9.6 (3.2 to 21.0) | 7.7 (2.1 to 18.5) | 5.8 (1.2 to 15.9) | 5.8 (1.2 to 15.9) | 11.5 (4.4 to 23.4) |
| Muscle pain:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0.0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) |
| Muscle pain:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Joint pain:Any | 13.5 (5.6 to 25.8) | 9.6 (3.2 to 21.0) | 13.5 (5.6 to 25.8) | 9.6 (3.2 to 21.0) | 13.5 (5.6 to 25.8) | 11.5 (4.4 to 23.4) | 5.8 (1.2 to 15.9) |
| Joint pain:Mild | 9.6 (3.2 to 21.0) | 5.8 (1.2 to 15.9) | 3.8 (0.5 to 13.2) | 7.7 (2.1 to 18.5) | 9.6 (3.2 to 21.0) | 9.6 (3.2 to 21.0) | 1.9 (0.0 to 10.3) |
| Joint pain:Moderate | 3.8 (0.5 to 13.2) | 3.8 (0.5 to 13.2) | 9.6 (3.2 to 21.0) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 3.8 (0.5 to 13.2) |
| Joint pain:Severe | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
| Joint pain:Grade 4 | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 19.2 (9.6 to 32.5) | 5.8 (1.2 to 15.9) | 19.2 (9.6 to 32.5) | 13.5 (5.6 to 25.8) | 26.9 (15.6 to 41.0) | 28.8 (17.1 to 43.1) | 21.2 (11.1 to 34.7) |
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 1.9 (0.0 to 10.3) | 0 (0.0 to 6.8) | 0 (0.0 to 6.8) |
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.
| percentage of participants | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination | 21.2 (11.1 to 34.7) | 23.1 (12.5 to 36.8) | 28.8 (17.1 to 43.1) | 19.2 (9.6 to 32.5) | 34.6 (22.0 to 49.1) | 26.9 (15.6 to 41.0) | 34.6 (22.0 to 49.1) |
Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.
| Microgram per milliliter | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Ia | 30.880 (13.301 to 71.691) | 20.341 (8.533 to 48.486) | 24.723 (10.577 to 57.785) | 41.826 (17.740 to 98.613) | 21.125 (10.121 to 44.094) | 17.829 (7.542 to 42.149) | 0.755 (0.372 to 1.536) |
| Ib | 2.060 (0.891 to 4.762) | 2.051 (0.952 to 4.417) | 3.174 (1.368 to 7.365) | 3.639 (1.426 to 9.289) | 2.742 (1.102 to 6.820) | 1.948 (0.785 to 4.836) | 0.034 (0.019 to 0.059) |
| II | 31.851 (17.303 to 58.630) | 21.919 (11.544 to 41.618) | 26.980 (14.586 to 49.904) | 57.011 (31.917 to 101.832) | 37.258 (20.764 to 66.853) | 31.786 (17.490 to 57.770) | 0.187 (0.126 to 0.279) |
| III | 5.683 (3.002 to 10.760) | 4.531 (2.290 to 8.965) | 4.979 (2.346 to 10.571) | 12.806 (6.221 to 26.365) | 5.559 (2.724 to 11.345) | 3.766 (1.887 to 7.517) | 0.081 (0.054 to 0.122) |
| IV | 2.915 (1.712 to 4.964) | 5.149 (2.913 to 9.102) | 4.924 (3.077 to 7.879) | 4.908 (2.890 to 8.336) | 4.303 (2.605 to 7.107) | 7.018 (4.518 to 10.903) | 0.046 (0.027 to 0.078) |
| V | 2.985 (1.346 to 6.619) | 3.368 (1.477 to 7.679) | 4.702 (2.033 to 10.878) | 5.142 (2.403 to 11.005) | 3.991 (1.984 to 8.031) | 6.760 (3.230 to 14.146) | 0.143 (0.084 to 0.244) |
Collected over Local reactions and systemic events: within 14 days after vaccination on Day 1 and all AEs other than local reactions and systemic events: within 6 Months after vaccination on Day 1. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GBS6 5 Microgram With Aluminum Phosphate | 0/52 (0%) | 1/52 (1.9%) | 40/52 (76.9%) |
| GBS6 5 Microgram Without Aluminum Phosphate | 0/52 (0%) | 0/52 (0%) | 35/52 (67.3%) |
| GBS6 10 Microgram With Aluminum Phosphate | 1/52 (1.9%) | 1/52 (1.9%) | 39/52 (75%) |
| GBS6 10 Microgram Without Aluminum Phosphate | 0/52 (0%) | 0/52 (0%) | 36/52 (69.2%) |
| GBS6 20 Microgram With Aluminum Phosphate | 0/52 (0%) | 1/52 (1.9%) | 41/52 (78.8%) |
| GBS6 20 Microgram Without Aluminum Phosphate | 0/52 (0%) | 0/52 (0%) | 36/52 (69.2%) |
| Placebo | 0/52 (0%) | 0/52 (0%) | 35/52 (67.3%) |
| Event | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/52 | 0/52 | 0/52 | 0/52 | 0/52 | 0/52 | 0/52 |
| Completed suicidePsychiatric disorders | 0/52 | 0/52 | 1/52 | 0/52 | 0/52 | 0/52 | 0/52 |
| MetrorrhagiaReproductive system and breast disorders | 0/52 | 0/52 | 0/52 | 0/52 | 1/52 | 0/52 | 0/52 |
| Event | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo |
|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 28/52 | 17/52 | 25/52 | 20/52 | 27/52 | 13/52 | 8/52 |
| FatigueGeneral disorders | 22/52 | 17/52 | 18/52 | 14/52 | 26/52 | 20/52 | 18/52 |
| HeadacheNervous system disorders | 21/52 | 19/52 | 17/52 | 20/52 | 21/52 | 16/52 | 22/52 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/52 | 13/52 | 10/52 | 10/52 | 10/52 | 12/52 | 10/52 |
| DiarrhoeaGastrointestinal disorders | 7/52 | 11/52 | 7/52 | 11/52 | 11/52 | 9/52 | 6/52 |
| Nausea/vomitingGastrointestinal disorders | 7/52 | 3/52 | 6/52 | 9/52 | 5/52 | 6/52 | 11/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/52 | 5/52 | 7/52 | 5/52 | 7/52 | 6/52 | 3/52 |
| Upper respiratory tract infectionInfections and infestations | 1/52 | 0/52 | 3/52 | 1/52 | 4/52 | 6/52 | 3/52 |
| SinusitisInfections and infestations | 4/52 | 2/52 | 2/52 | 1/52 | 2/52 | 0/52 | 2/52 |
| InfluenzaInfections and infestations | 0/52 | 0/52 | 2/52 | 0/52 | 0/52 | 0/52 | 3/52 |
Safety population included all participants who received either GBS6 vaccine or placebo.
| Age, Continuous(years) | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 32.9 ± 8.43 | 34.7 ± 9.35 | 32.8 ± 8.31 | 31.9 ± 8.10 | 33.2 ± 8.67 | 30.5 ± 8.25 | 32.8 ± 8.74 | 32.7 ± 8.57 |
| Sex: Female, Male(Participants) | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 35 | 41 | 32 | 33 | 35 | 37 | 43 | 256 |
| Male | 17 | 11 | 20 | 19 | 17 | 15 | 9 | 108 |
| Ethnicity (NIH/OMB)(Participants) | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 2 | 2 | 5 | 1 | 5 | 21 |
| Not Hispanic or Latino | 50 | 47 | 50 | 49 | 47 | 51 | 47 | 341 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | GBS6 5 Microgram With Aluminum Phosphate | GBS6 5 Microgram Without Aluminum Phosphate | GBS6 10 Microgram With Aluminum Phosphate | GBS6 10 Microgram Without Aluminum Phosphate | GBS6 20 Microgram With Aluminum Phosphate | GBS6 20 Microgram Without Aluminum Phosphate | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| White | 44 | 41 | 46 | 41 | 45 | 46 | 44 | 307 |
| Black or African American | 5 | 9 | 5 | 8 | 4 | 4 | 7 | 42 |
| Other | 2 | 1 | 0 | 2 | 2 | 2 | 0 | 9 |
| Asian | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 5 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2017 to primary completion in Jun 2018, 12 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 12 phase 2 interventional studies under Streptococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.